Cerus Corporation
HealthcareNASDAQ:CERS · NASDAQ Global Market
-$0.03 today
Vol 2.22M · Avg 2.27M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-24.3%
avg -75.9%
ROIC
-21.7%
avg -39.3%
ROA
-7.0%
avg -31.5%
Analysis
ROA is currently the strongest return metric at -7.0% versus its period average of -31.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
William Greenman | President, Chief Executive Officer & Chairman | $1.55M | — | 59 | $5.00M | 2.49% |
Vivek K. Jayaraman | Chief Operating Officer | $964,154.00 | — | 51 | $1.66M | 0.83% |
Kevin D. Green | Vice President of Finance & Chief Financial Officer | $831,572.00 | — | 54 | $1.24M | 0.62% |
Richard J. Benjamin | Chief Medical Officer | $792,709.00 | — | 66 | $777,361.00 | 0.39% |
Chrystal Jensen | Chief Legal Officer, General Counsel & Secretary | $755,504.00 | — | 55 | $1.15M | 0.57% |
Laurence Corash | Co-Founder & Chief Scientific Officer | $697,774.00 | — | 82 | $2.34M | 1.17% |
Carol Moore | Senior Vice President of Regulatory Affairs, Quality & Clinical | $438,239.00 | — | 76 | $205,073.00 | 0.10% |
Timothy J. Lee | Head of Investor Relation | — | — | — | $205,073.00 | 0.10% |
Nina Mufti | Senior Vice President of Research & Development | — | — | — | — | — |
Lainie Corten | Vice President of Global Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$31,250.00
Sells
17
$2.48M
Net Sentiment
$2.45M
Net selling
Most Active
Benjamin Richard J
5 transactions
1–10 of 18
Analysis
Insiders reported 1 buys worth $31,250.00 and 17 sells worth $2.48M over the last 12 months. That adds up to net selling of $2.45M. Benjamin Richard J was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -2.3% | +18.5% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -2.3% over three years. Forward estimates point to Revenue at +18.5% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
NeuroPace, Inc.
NASDAQ:NPCE
$533.23M
TruBridge, Inc.
NASDAQ:TBRG
$391.78M
908 Devices Inc.
NASDAQ:MASS
$312.72M
Senseonics Holdings, Inc.
NASDAQ:SENS
$299.93M
Sight Sciences, Inc.
NASDAQ:SGHT
$279.12M
Alpha Teknova, Inc.
NASDAQ:TKNO
$225.18M
RxSight, Inc.
NASDAQ:RXST
$194.98M
Quanterix Corporation
NASDAQ:QTRX
$146.03M
CVRx, Inc.
NASDAQ:CVRX
$133.48M
SANUWAVE Health, Inc.
NASDAQ:SNWV
$128.21M
Who manages CERS?
Cerus Corporation (CERS) lists 10 active executives. The top listed executive is William Greenman, President, Chief Executive Officer & Chairman.
Are CERS insiders buying or selling?
Recent insider activity shows net selling of $2.31M.
Explore More
Continue the stock analysis
Jump to another research area for this company.